Bristol-Myers' Hepatitis C combo gets breakthrough designation

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

The FDA has granted breakthrough designation to Bristol-Myers Squibs' (BMY) Daclatasvir and Asunaprevir combination oral treatment for Hepatitis C.

Specifically, the designation applies to the treatment of genotype 1b chronic hepatitis C and is based on the results of an ongoing Phase III trial.

The FDA's decision comes after European regulators said they would give an accelerated review to Daclatasvir when used in combination with other drugs. (PR)